National Cancer Research Institute
4
22M
4
0.18
1
- Areas of investment
Summary
In 2001 was created National Cancer Research Institute, which is appeared as Corporate Investor. The venture was found in Europe in United Kingdom. The main office of represented Corporate Investor is situated in the London.
The typical case for the fund is to invest in rounds with 1 participant. Despite the National Cancer Research Institute, startups are often financed by J. Hunt Holdings, Sun Mountain Capital. In the next rounds fund is usually obtained by National Cancer Institute SBIR Development Center.
Moreover, a startup needs to be at the age of more than 20 years to get the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline The Case Comprehensive Cancer Center (Case CCC), Agilvax Among the most successful fund investment fields, there are Hospital, Charity.
The important activity for fund was in 2018. The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 1 - 5 millions dollars.
Investments analytics
Analytics
- Total investments
- 4
- Lead investments
- 1
- Rounds per year
- 0.18
- Investments by industry
- Biotechnology (3)
- Health Care (2)
- Medical (2)
- Hospital (1)
- Charity (1) Show 1 more
- Investments by region
-
- United States (4)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 52
- Group Appearance index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| SURGE Therapeutics | 17 Oct 2022 | Biotechnology | Early Stage Venture | 26M | United States, Massachusetts, Cambridge |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.